Medicare seniors get drug coinsurance tied to real prices, not inflated list prices

What it does

This bill requires Medicare Part D drug plans to calculate patient coinsurance (the percentage of drug cost patients pay) based on the drug's actual negotiated price after discounts, not the inflated list price, starting in 2026. Seniors would pay less out-of-pocket when the net price is lower than the list price, shifting the calculation to reflect what insurers actually pay for drugs.

Why we flagged it

The bill's sole operative mechanism is a pricing calculation change in Medicare Part D that reduces senior out-of-pocket costs by tying coinsurance to actual negotiated prices rather than list prices. This is a direct consumer-protection measure within the existing Medicare framework.

What the text implies

• Pharmaceutical manufacturers may respond by raising list prices further to offset the reduced coinsurance burden, since the bill only constrains what seniors pay—not what manufacturers charge or what plans pay.
• The bill's carve-out for drugs in paragraphs (8) and (9) (specialty tier and catastrophic coverage) means high-cost biologics and drugs in the catastrophic phase remain unaffected, limiting the bill's reach to mid-tier drugs.
• Plan sponsors may adjust formulary placement or copayment structures to offset lower coinsurance revenue, potentially shifting costs to other plan design elements.
• The definition of 'net price' depends on DIR (Direct and Indirect Remuneration) reporting rules under 42 CFR 423.100; changes to those regulations could alter the bill's effect without legislative amendment.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Seniors enrolled in Medicare Part D will pay lower coinsurance amounts when drug net prices are below list prices, reducing their out-of-pocket drug costs. The bill aligns what patients pay with what insurers actually negotiate, eliminating the gap that currently forces seniors to subsidize the difference between inflated list prices and actual negotiated discounts.

Who stands to gain

• Medicare Part D beneficiaries (seniors)
• Medicare Advantage plans with Part D coverage (reduced coinsurance liability)

Named in the bill

Medicare Part D, Social Security Act Section 1860D-2, 42 CFR 423.100, Detailed DIR Report, Prescription drug plans, MA-PD plans, Pharmaceutical manufacturers

Where it stands

1 cosponsor: 1 Republicans.

• Jul 31, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 31, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,282,990 in lobbying spend. A filing names 37 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Jacky Rosen, the sponsor, reported $207,550 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.